Author Archives: admin


Stem Cell Clinic > Articles by: admin

Craft Cannabis Brand, Broken Coast, Launches Latest Artisanal Strain, ‘Milk & Cookies’ for Avid Indica Enthusiasts

By Stem Cell Medical Center

TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a leading lifestyle and consumer packaged goods company, announced the release of premium cannabis brand, BROKEN COAST’s latest small batch flower strain, 'Milk & Cookies', joining the brand's renowned craft cannabis portfolio of Cherry Cheesecake, EmergenZ, Sour OG, Holy Grail Kush, and Amnesia Haze. This potent indica strain features sweet vanilla and nutty earthy flavors, making it the perfect choice for unwinding after a long day or sharing with friends.

See the original post here:
Craft Cannabis Brand, Broken Coast, Launches Latest Artisanal Strain, ‘Milk & Cookies’ for Avid Indica Enthusiasts

Starton Therapeutics Strengthens Clinical Development Strategy Following Successful Scientific Advisory Board Meeting at ASCO 2024

By Stem Cell Medical Center

PARAMUS, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, is pleased to announce its successful scientific Advisory Board meeting held during the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. Led by Starton’s Scientific Board members and Chief Medical Officer, the meeting was attended by recognized experts and key opinion leaders in the field of oncology and yielded significant insights and outcomes that will shape the Company’s research and development efforts in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM).

Link:
Starton Therapeutics Strengthens Clinical Development Strategy Following Successful Scientific Advisory Board Meeting at ASCO 2024

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

By Global News Feed

WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in two upcoming investor conferences in September 2024 as follows:

The rest is here:
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

By Global News Feed

WESTLAKE VILLAGE, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference.

Excerpt from:
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for…

By Global News Feed

WOBURN, Mass., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that a late-breaking abstract presenting the primary analysis of the IGNYTE clinical trial has been selected for oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 being held September 13-17, 2024, in Barcelona.

Read the original:
Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for...

Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan

By Global News Feed

TAMPA, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) today provided an update on development efforts for its itraconazole formulation for the treatment of Basal Cell Carcinomas in patients with Basal Cell Carcinoma Nevus Syndrome, otherwise known as Gorlin Syndrome. Inhibitor has allied with The Gorlin Syndrome Alliance and sought supportive guidance from the accomplished and highly-experienced members of its Scientific Advisory Board in efforts to pursue an expeditious path to acceptance by the U.S. Food and Drug Administration (FDA).

More:
Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan

→←